MedTrace Logo

Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients

NCT05360537 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-12-15

No results posted yet for this study

Summary

The study aims to evaluate the effects of Insulin Degludec/Liraglutide on glycemic variability assessed by continuous glycemic monitoring with the function time in range, serum markers of inflammation, markers of endothelial dysfunction and a possible correlation with intra and extra-hospital mortality rates in a group of hospitalized diabetic patients compared to a control group of in-patient diabetic in treatment on insulin Basal-bolus.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin Degludec / Liraglutide Injectable Product

administration of Insulin Degludec/Liraglutide

DRUG

Insulin Glargine

Administration of glargine insulin

Sponsors & Collaborators

  • University of Palermo

    lead OTHER

Principal Investigators

  • Antonino Tuttolomondo, Professor · University of Palermo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2021-12-01
Completion
2022-04-20

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05360537 on ClinicalTrials.gov